Quantitative assays of mdm2 ubiquitin ligase activity and other ubiquitin-utilizing enzymes for inhibitor discovery

被引:8
作者
Auger, KR [1 ]
Copeland, RA [1 ]
Lai, ZH [1 ]
机构
[1] GlaxoSmithKline Inc, Collegeville, PA USA
来源
UBIQUITIN AND PROTEIN DEGRADATION, PT B | 2005年 / 399卷
关键词
D O I
10.1016/S0076-6879(05)99046-0
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
Mdm2 is a negative regulator of p53 activity and functions as an E3 ubiquitin ligase of p53. Inhibition of mdm2 E3 ligase activity will block ubiquitination and subsequent proteasome-mediated degradation of p53, resulting in the stabilization of p53 protein that could lead to the restoration of its tumor-suppressor activity. This chapter describes quantitative biochemical assays for mdm2 E3 activity that can be applied to other ubiquitin-utilizing enzyme systems. Our unique assay format relies on the generation of labeled Ub-E2 conjugate that functions as a substrate for the E3 ligase enzyme. Reducing the E1-E2-E3 ubiquitin cascade to a single enzyme (M) and bisubstrate (Ub-E2 and target protein) reaction makes it possible to carry out detailed biochemical characterization of the reaction mechanism, high-throughput screening to identify inhibitors of specific E3 ligases, and detailed characterization of the mode of inhibitor interactions with the target enzyme. In addition, preforming the Ub-E2 conjugate as an enzyme substrate for inhibitor screening minimizes interference from thiol-modifying compounds and from nucleotide analogs and other ATP-interfering compounds that might affect the El reaction. Using this type of format, we were able to identify small molecule inhibitors of mdm2 E3 ligase activity that are selective against El and other E3 ligases, including mdm2's own autoubiquitination activity. Detailed protocols on the labeling of Ub, the generation of Ub-E2, and the use of Ub-E2 in the E3 ligase reaction for inhibitor discovery and characterization are provided.
引用
收藏
页码:701 / 717
页数:17
相关论文
共 30 条
[1]   Development of a ubiquitin transfer assay for high throughput screening by fluorescence resonance energy transfer [J].
Boisclair, MD ;
McClure, C ;
Josiah, S ;
Glass, S ;
Bottomley, S ;
Kamerkar, S ;
Hemmilä, I .
JOURNAL OF BIOMOLECULAR SCREENING, 2000, 5 (05) :319-328
[2]   p53: 25 years of research and more questions to answer [J].
Bourdon, JC ;
De Laurenzi, V ;
Melino, G ;
Lane, D .
CELL DEATH AND DIFFERENTIATION, 2003, 10 (04) :397-399
[3]  
Brooks CL, 2004, CELL CYCLE, V3, P436
[4]  
Copeland R., 2005, EVALUATION ENZYME IN, V1st
[5]  
Copeland R. A., 2004, ENZYMES PRACTICAL IN
[6]   RING finger ubiquitin protein ligases: implications for tumorigenesis, metastasis and for molecular targets in cancer [J].
Fang, S ;
Lorick, KL ;
Jensen, JP ;
Weissman, AM .
SEMINARS IN CANCER BIOLOGY, 2003, 13 (01) :5-14
[7]   Mdm2 is a RING finger-dependent ubiquitin protein ligase for itself and p53 [J].
Fang, SY ;
Jensen, JP ;
Ludwig, RL ;
Vousden, KH ;
Weissman, AM .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2000, 275 (12) :8945-8951
[8]   Functions of the MDM2 oncoprotein [J].
Freedman, DA ;
Wu, L ;
Levine, AJ .
CELLULAR AND MOLECULAR LIFE SCIENCES, 1999, 55 (01) :96-107
[9]   The ubiquitin-proteasome proteolytic pathway: Destruction for the sake of construction [J].
Glickman, MH ;
Ciechanover, A .
PHYSIOLOGICAL REVIEWS, 2002, 82 (02) :373-428
[10]   Polyubiquitination of p53 by a ubiquitin ligase activity of p300 [J].
Grossman, SR ;
Deato, ME ;
Brignone, C ;
Chan, HM ;
Kung, AL ;
Tagami, H ;
Nakatani, Y ;
Livingston, DM .
SCIENCE, 2003, 300 (5617) :342-344